Module 2 - Atrial fibrillation (AF) burden: the need for a new definition
In this module, we will review current approaches to the concept of AF burden as well as their limitations. A new unified definition of AF burden will be discussed.
Wolfram Doehner, MD, PhD, FESC, FHFA
Professor of Interdisciplinary Stroke Research at the Charité - Universitätsmedizin Berlin, Germany.
Dr Doehner is a cardiologist and specialist in internal medicine and nutritional medicine. He works at the Berlin Institute of Health -Center for Regenerative Therapies (BCRT) and at the Dept. of Cardiology at the Virchow hospital of the Charité – Universitätsmedizin Berlin. He also holds a faculty position at the Center for Stroke Research Berlin (CSB) and a visiting professorship at the Karls University, Prague, Czech Republic.His academic work includes more than 490 publications in peer-reviewed journals and book chapters, h-index 73, total citations >24,000 (Research Gate, Sept.22). He is the associate editor of several scientific journals. He currently holds various positions within the European Society of Cardiology (ESC): founding member and chair of the ESC Council on Stroke (2018-20), co-chair of the HFA Congress 2020, secretary of the rehabilitation section of the European Association on Preventive Cardiology (EAPC, 2018-20), member of the ESC clinical program committee (2014-2020) and member of the Board of the ESC (2022 – ongoing).
1.
Review the rationale for assessing atrial fibrillation (AF) burden with a risk-stratification approach
2.
Discuss the clinical utility of the various technologies for detection and monitoring of AF burden
3.
Review the current definition of AF burden, its relevance in clinical practice, and its limitations
Faculty Disclosure:
Wolfram Doehner, MD, PhD, FESC, FHFA
- Research support: EU-FP7, HORIZON-2020, German Ministry of Education and Research, German Center of Cardiovascular Research ,Vifor Pharma, ZS Pharma
- Consulting and speaker honoraria: AiMediq, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Ferrer, Lilly, Medtronic, Pfizer, Sanofi, Sphingotec, Vifor Pharma.
